Meilleure Health International Industry Group Limited has released its unaudited interim results for the six months ended June 30, 2025. The company reported a decrease in revenue, which dropped by approximately 41.7% from HK$30.0 million in the same period in 2024 to HK$17.5 million in 2025. This decline was primarily due to a decrease in the sale of construction materials by approximately HK$8.7 million and a reduction in the sale of healthcare-related products by approximately HK$3.5 million, reflecting adverse market conditions. The gross profit for the period was approximately HK$14.2 million, down from HK$15.4 million in the previous year, marking a decrease of about 7.8%. Despite the decline in gross profit, the gross profit margin improved to 81.1% from 51.3% in the prior year. Interest income saw an increase from HK$8.9 million in 2024 to HK$14.8 million in 2025, and there was a positive impact from foreign exchange gains, which rose from HK$4.4 million to HK$5.8 million. However, these gains were partially offset by a significant reduction in fair value gains on investments at FVTPL, which decreased from HK$17.8 million to HK$0.9 million. Additionally, there was an unfavorable shift in loss allowance for trade and other receivables, moving from a reversal of impairment loss of HK$4.2 million in 2024 to an impairment loss of HK$1.3 million in 2025. No outlook or guidance for future periods is provided in the report.